Browsing by Author "Fajardo, C."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Continuous renal replacement therapy in neonates and young infants during extracorporeal membrane oxygenation
    (SAGE PUBLICATIONS LTD, 2007) Cavagnaro, F.; Kattan, J.; Godoy, L.; Gonzalez, A.; Vogel, A.; Rodriguez, J. I.; Faunes, M.; Fajardo, C.; Becker, P.
    Extracorporeal membrane oxygenation (ECMO) is a therapy that ensures adequate tissue oxygen delivery in patients suffering cardiac and/or respiratory failure that are unresponsive to conventional therapy. During ECMO, it is common to see a decrease in urine output that may be associated with acute renal failure. In this context, continuous renal replacement therapy (CRRT) should be considered. Our aim is to evaluate a pioneer experience in Latin America, related to the use of CRRT in a group of neonatal-pediatric patients during ECMO. We conducted a retrospective review of patients treated with ECMO at our institution between May 2003 and May 2005. Twelve infants were treated with ECMO, six of them also underwent CRRT The main reasons for CRRT initiation were fluid overload and progressive azotemia. Observed complications were clots in the filter and excessive ultraffitration. CRRT was successful in fluid management and solute clearance in all patients. Discharge survival rate was 83%, all of them with normal renal function. Concurrent CRRT with ECMO is technically feasible and efficacious in the management of fluid overload and solute clearance. We report the first experience with these therapies in a Latin American neonatalpediatric ECMO program associated with the Extracorporeal Life Support Organization.
  • Thumbnail Image
    Item
    Renal protection in patients undergoing cardiopulmonary bypass with preoperative abnormal renal function
    (LIPPINCOTT WILLIAMS & WILKINS, 1998) Lema, G.; Urzua, J.; Jalil, R.; Canessa, R.; Moran, S.; Sacco, C.; Medel, J.; Irarrazaval, M.; Zalaquett, R.; Fajardo, C.; Meneses, G.
    We prospectively studied the effects of renal protection intervention in 17 patients with preoperative abnormal renal function (plasma creatinine >1.5 mg/dL) scheduled for elective coronary surgery. Patients were randomized to either dopamine 2.0 ,mu g.kg(-1).min(-1) (Group 1, n = 10) or perfusion pressure >70 mm Hg during cardiopulmonary bypass (CPB) (Group 2, n = 7). Glomerular filtration rate and effective renal plasma flow were measured with inulin and I-125-hippuran clearances before the induction of anesthesia, after sternotomy and before CFB, during hypo-and normothermic CPB, after sternal closure, and 1 h postoperatively. Plasma and urine electrolytes were measured, and free water, osmolar, and creatinine clearances, as well as fractional excretion of sodium and potassium, were calculated ed before and after surgery. Significant differences between groups were found before CPB for glomerular filtration rate (higher in Group 1), urine output (2.0 vs 0.29 mL/min in Group 1 versus Group 2), urinary creatinine (66 vs 175 mg/dL), urinary osmolarity (370 vs 627 mOsm/L), osmolar clearance (2.1 vs 0.7 mL/min), and urinary potassium (33 vs 71 mEq/L). There were no differences between groups during hypo-and normothermic CPB. After CPB, the only difference was a slightly higher urinary creatinine in Group 2. Renal plasma flow was lower than normal in all patients before the induction of anesthesia. A nonsignificant trend toward increased flow was seen during hypothermic CPB. Filtration fraction was high before CPB, which suggests efferent arteriolar vasoconstriction, descending toward normal during and after CPB. The same pattern of changes was present in both groups. In conclusion, there were no clinically relevant differences between the two treatment modalities during and after CPB. However, significant differences were observed before CPB, when dopamine seemed to partially revert renal vasoconstriction. Implications: Two protective interventions were compared in patients undergoing heart surgery to prevent deterioration of renal function; these were dopamine infusion throughout the operation and phenylephrine infusion during cardiopulmonary bypass. We found clinically relevant differences only during surgery before cardiopulmonary bypass.